Imaging the folate receptor on cancer cells with 99mTc- etarfolatide: Properties, clinical use, and future potential of folate receptor imaging

Journal of Nuclear Medicine

Volumn 55, Issue 5, 2014, Pages 701-704

  Maurer, Alan H ^a   Elsinga, Philip ^b   Fanti, Stefano ^c   Nguyen, Binh ^d   Oyen, Wim J G ^e   Weber, Wolfgang A ^f  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d Endocyte Inc   (United States)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Folate receptor; Imaging; SPECT; SPECT CT

Indexed keywords

CARBOPLATIN; DOCETAXEL; DOXORUBICIN; ETARFOLATIDE TC 99M; FARLETUZUMAB; FOLATE RECEPTOR; FOLATE RECEPTOR 1; FOLATE RECEPTOR 2; PACLITAXEL; VINTAFOLIDE;

CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL ASSESSMENT; CONJUGATION; DISEASE ASSOCIATION; DOWN REGULATION; DRUG EFFECT; DRUG SAFETY; HUMAN; ISOTOPE LABELING; LOWER ABDOMINAL PAIN; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM TOLERATED DOSE; MOLECULAR IMAGING; NAUSEA; OVARY CANCER; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SOLID TUMOR; VOMITING;

99MTC-ETARFOLATIDE; FOLATE RECEPTOR; IMAGING; SPECT; SPECT/CT;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; CONTRAST MEDIA; FOLATE RECEPTORS, GPI-ANCHORED; FOLIC ACID; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFLAMMATION; NEOPLASM STAGING; NEOPLASMS; ORGANOTECHNETIUM COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; TECHNETIUM; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; VINCA ALKALOIDS; WHOLE BODY IMAGING;

EID: 84901327650     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.133074     Document Type: Review

References (35)

1. Teng L, Xie J, Teng L, Lee RJ. Clinical translation of folate receptor-targeted therapeutics. Expert Opin Drug Deliv. 2012;9:901-908.
2. Elnakat H, Ratnam M. Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev. 2004;56:1067-1084.
3. Naumann RW, Coleman RL, Burger RA, et al. PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2013;31:4400-4406.
4. Muller C, Schibli R. Folate-receptor targeted radionuclide imaging agents. In: Jackman AL, Leamon CP, eds. Targeted Drug Strategies for Cancer and Inflammation. New York, NY: Springer; 2011:65-92.
5. Kalli KR, Oberg AL, Keeney GL, et al. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol. 2008;108:619-626.
6. Chen YL, Chang MC, Huang CY, et al. Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response. Mol Oncol. 2012;6:360-369.
7. Siu MK, Kong DS, Chan HY, et al. Paradoxical impact of two folate receptors, FRa and RFC, in ovarian cancer: effect on cell proliferation, invasion and clinical outcome. PLoS ONE. 2012;7:e47201.
8. Low PS, Henne WA, Doorneweerd DD. Discovery and development of folic-acidbased receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc Chem Res. 2008;41:120-129.
9. Armstrong DK, White AJ, Weil SC, Phillips M, Coleman RL. Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer. Gynecol Oncol. 2013;129:452-458.
10. Xia W, Hilgenbrink AR, Matteson EL, Lockwood MB, Cheng JX, Low PS. A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages. Blood. 2009;113:438-446.
11. Fisher RE, Siegel BA, Edell SL, et al. Exploratory study of 99mTc-EC20 imaging for identifying patients with folate receptor-positive solid tumors. J Nucl Med. 2008;49:899-906.
12. Almendro V, Marusyk A, Polyak K. Cellular heterogeneity and molecular evolution in cancer. Annu Rev Pathol. 2013;8:277-302.
13. Morris RT, Joyrich RN, Naumann RW, et al. Phase 2 study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide). Ann Oncol. In press.
14. Buist MR, Kenemans P, den Hollander W, et al. Kinetics and tissue distribution of the radiolabeled chimeric monoclonal antibody MOv18 IgG and F(ab9)2 fragments in ovarian carcinoma patients. Cancer Res. 1993;53:5413-5418.
15. Siegel BA, Dehdashti F, Mutch DG, et al. Evaluation of 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results. J Nucl Med. 2003;44:700-707.
16. Banerjee S, Pillai MR, Ramamoorthy N. Evolution of Tc-99m in diagnostic radiopharmaceuticals. Semin Nucl Med. 2001;31:260-277.
17. Leamon CP, Parker MA, Vlahov IR, et al. Synthesis and biological evaluation of EC20: a new folate-derived, 99mTc-based radiopharmaceutical. Bioconjug Chem. 2002;13:1200-1210.
18. Reddy JA, Xu LC, Parker N, Vetzel M, Leamon CP. Preclinical evaluation of 99mTc-EC20 for imaging folate receptor-positive tumors. J Nucl Med. 2004;45:857-866.
19. HenneWA, Rothenbuhler R, Ayala-Lopez W, XiaW, Varghese B, Low PS. Imaging sites of infection using a 99mTc-labeled folate conjugate targeted to folate receptor positive macrophages. Mol Pharm. 2012;9:1435-1440.
20. Vaitilingam B, Chelvam V, Kularatne SA, Poh S, Ayala-Lopez W, Low PS. A folate receptor-a-specific ligand that targets cancer tissue and not sites of inflammation. J Nucl Med. 2012;53:1127-1134.
21. Müller C. Folate-based radiotracers for PET imaging: update and perspectives. Molecules. 2013;18:5005-5031.
22. Bettio A, Honer M, Müller C, et al. Synthesis and preclinical evaluation of a folic acid derivative labeled with 18F for PET imaging of folate receptor-positive tumors. J Nucl Med. 2006;47:1153-1160.
23. Ross TL, Honer M, Müller C, Groehn V, Schibli R, Ametamey SM. A new 18Flabeled folic acid derivative with improved properties for the PET imaging of folate receptor-positive tumors. J Nucl Med. 2010;51:1756-1762.
24. Betzel T, Müller C, Groehn V, et al. Radiosynthesis and preclinical evaluation of 39-Aza-29-[18F]fluorofolic acid: a novel PET radiotracer for folate receptor targeting. Bioconjug Chem. 2013;24:205-214.
25. Fischer CR, Müller C, Reber J, et al. [18F]fluoro-deoxy-glucose folate: a novel PET radiotracer with improved in vivo properties for folate receptor targeting. Bioconjug Chem. 2012;23:805-813.
26. Fani M, Tamma ML, Nicolas GP, et al. In vivo imaging of folate receptor positive tumor xenografts using novel 68Ga-NODAGA-folate conjugates. Mol Pharm. 2012;9: 1136-1145.
27. Fani M, Wang X, Nicolas G, et al. Development of new folate-based PET radiotracers: preclinical evaluation of 68Ga-DOTA-folate conjugates. Eur J Nucl Med Mol Imaging. 2011;38:108-119.
28. O'Shannessy DJ, Yu G, Smale R, et al. Folate receptor alpha expression in lung cancer: diagnostic and prognostic significance. Oncotarget. 2012;3:414-425.
29. van Dam GM, Themelis G, Crane LM, et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-a targeting: first in-human results. Nat Med. 2011;17:1315-1319.
30. Ayala-Ĺopez W, Xia W, Varghese B, Low PS. Imaging of atherosclerosis in apoliprotein e knockout mice: targeting of a folate-conjugated radiopharmaceutical to activated macrophages. J Nucl Med. 2010;51:768-774.
31. Turk MJ, Breur GJ, Widmer WR, et al. Folate-targeted imaging of activated macrophages in rats with adjuvant-induced arthritis. Arthritis Rheum. 2002;46: 1947-1955.
32. Paulos CM, Turk MJ, Breur GJ, Low PS. Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis. Adv Drug Deliv Rev. 2004;56:1205-1217.
33. Matteson EL, Lowe VJ, Prendergast FG, et al. Assessment of disease activity in rheumatoid arthritis using a novel folate targeted radiopharmaceutical Folatescan. Clin Exp Rheumatol. 2009;27:253-259.
34. Piscaer TM, Müller C, Mindt TL, et al. Imaging of activated macrophages in experimental osteoarthritis using folate-targeted animal single-photon-emission computed tomography/computed tomography. Arthritis Rheum. 2011;63:1898-1907.
35. Winkel LC, Groen HC, van Thiel BS, et al. Folate receptor-targeted single-photon emission computed tomography/computed tomography to detect activated macrophages in atherosclerosis: can it distinguish vulnerable from stable atherosclerotic plaques? Mol Imaging. 2013;12:1-5.